Research Article
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment
Table 1
Characteristics of the analysed trials.
| | Study | Design | Primary endpoint | Number of patients in the experimental arm | Number of patients in the control arm | Experimental drug (OS) | Control arm (OS) | Delta OS |
| | CELESTIAL | III | OS | 470 | 237 | Cabozantinib (10.2 months) | Placebo (8.0 months) | 2.2 months | | REACH | III | OS | 283 | 282 | Ramucirumab+ BSC (9.2 months) | Placebo+ BSC (7.6 months) | 1.6 months | | REACH-2 | III | OS | 197 | 95 | Ramucirumab+ BSC (8.5 months) | Placebo+ BSC (7.3 months) | 1.2 months | | RESOURCE | III | OS | 379 | 194 | Regorafenib+ BSC (10.6 months) | Placebo+ BSC (7.8 months) | 2.8 months |
|
|
OS: overall survival; BSC: best supportive care.
|
